Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097328 · ClinicalTrials.gov registry record · Phase 2
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Bradley A. McGregor, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03097328: Completed Phase 2 study, sponsored by Bradley A. McGregor, MD.
NCT03097328 is a Phase 2 study that has completed, run by Bradley A. McGregor, MD. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03097328, a Phase 2 study, has completed, sponsored by Bradley A. McGregor, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
Primary Outcome
The best overall response rate is the percentage of participants achieving complete response (CR) or partial response (PR) as the best response recorded on treatment based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). CR and PR must meet the following lesion criteria without having any new lesions as well: Target Lesion: (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Interventions
- DRUG TAK-228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 2 |
What the finished NCT03097328 record still lists
NCT03097328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which TAK-228 is the first listed.
NCT03097328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03097328 about?
NCT03097328 is a clinical study titled "Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma". This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.
What is the current status of trial NCT03097328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2017-08-01. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT03097328?
The interventions under investigation include: TAK-228 (DRUG).
Who is sponsoring clinical trial NCT03097328?
This trial is sponsored by Bradley A. McGregor, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03097328's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI